XORTX Therapeutics Files June 2024 Report
Ticker: XRTX · Form: 6-K · Filed: Jun 4, 2024 · CIK: 1729214
Sentiment: neutral
Topics: reporting, sec-filing
TL;DR
XORTX files routine June update, confirms 20-F filing.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on June 4, 2024, to report its activities for the month of June 2024. The filing indicates that the company is a foreign private issuer and will file annual reports under Form 20-F. Allen Davidoff, the Chief Executive Officer, signed the report.
Why It Matters
This filing provides an update on XORTX Therapeutics' regulatory reporting status and confirms their adherence to SEC filing requirements as a foreign private issuer.
Risk Assessment
Risk Level: low — This is a routine filing confirming the company's reporting status and is not indicative of new financial or operational developments.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- June 4, 2024 (date) — Filing date
FAQ
What type of report is XORTX Therapeutics Inc. filing?
XORTX Therapeutics Inc. is filing a Form 6-K, which is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
What period does this Form 6-K report cover?
This Form 6-K report is for the month of June 2024.
Who signed the Form 6-K on behalf of XORTX Therapeutics Inc.?
Allen Davidoff, Chief Executive Officer, signed the Form 6-K on behalf of XORTX Therapeutics Inc.
Does XORTX Therapeutics Inc. file annual reports under Form 20-F or Form 40-F?
XORTX Therapeutics Inc. indicates it files annual reports under cover of Form 20-F.
What is the filing date of this Form 6-K?
The filing date of this Form 6-K is June 4, 2024.
Filing Stats: 139 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2024-06-04 08:30:07
Filing Documents
- f6k_060424.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 6KB
- 0001171843-24-003256.txt ( ) — 11KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX Therapeutics Inc. (Registrant) Date: June 4, 2024 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 News Release dated June 4, 2024